NCT04218656View on ClinicalTrials.gov

DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Peripheral Artery Disease
Interventions
DRUG

Rivaroxaban 2.5 Mg Oral Tablet

2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).

Trial Locations (2)

6815 AD

Rijnstate hospital, Arnhem

6525 GA

Radboudumc, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT04218656 - DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease | Biotech Hunter | Biotech Hunter